SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001415889-16-005925
Filing Date
2016-05-16
Accepted
2016-05-16 15:23:23
Documents
51
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q fpmi10q_mar312016.htm 10-Q 584248
2 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARB ex31-1.htm EX-31.1 16694
3 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARB ex31-2.htm EX-31.2 17006
4 CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ex32-1.htm EX-32.1 6036
5 CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO U.S.C. SECTION 1350 AS ex32-2.htm EX-32.2 5838
  Complete submission text file 0001415889-16-005925.txt   2597059

Data Files

Seq Description Document Type Size
6 fpmi-20160331.xml EX-101.INS 385469
7 fpmi-20160331.xsd EX-101.SCH 31482
8 fpmi-20160331_cal.xml EX-101.CAL 37626
9 fpmi-20160331_def.xml EX-101.DEF 67111
10 fpmi-20160331_lab.xml EX-101.LAB 224299
11 fpmi-20160331_pre.xml EX-101.PRE 162965
Mailing Address 8 HILLSIDE AVENUE SUITE 207 MONTCLAIR NJ 07042
Business Address 8 HILLSIDE AVENUE SUITE 207 MONTCLAIR NJ 07042 973-744-1565
FLUOROPHARMA MEDICAL, INC. (Filer) CIK: 0001402785 (see all company filings)

IRS No.: 208325616 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 333-147193 | Film No.: 161653182
SIC: 2835 In Vitro & In Vivo Diagnostic Substances